title: Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
abstract: Resistance to antiretroviral drugs is generally conferred by specific amino acid substitutions, rather than insertions or deletions, in reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1). The exception to these findings is the amino acid insertions found in the beta3-beta4 loop of the RT enzyme in response to treatment with nucleoside reverse transcriptase inhibitors. This insert consists most commonly of two amino acids, but we describe in detail the evolution of a variant with an 8-amino-acid (aa) insert in a patient treated with zidovudine (ZDV) and 2'-3'-dideoxycytidine (ddC). The 24-nucleotide insert is a partial duplication of local sequences but also contains a sequence segment of unknown origin. Extensive sequence analysis of longitudinal patient samples indicated that the HIV-1 population prior to the start of therapy contained not the wild-type amino acid 215T in RT but a mixture with 215D and 215C. Treatment with ZDV and subsequent ZDV-ddC combination therapy resulted in the evolution of an HIV-1 variant with a typical ZDV resistance genotype (41L, 44D, 67N, 69D, 210W, 215Y), which was slowly replaced by the insert-containing variant (41L, 44D, insert at position 69, 70R, 210W, 215Y). The latter variant demonstrated increased resistance to a wide range of drugs, indicating that the 8-aa insert augments nucleoside analogue resistance. The gain in drug resistance of the insert variant came at the expense of a reduction in replication capacity when assayed in the absence of drugs. We compared these data with the resistance and replication properties of 133 insert-containing sequences of different individuals present in the ViroLogic database and found that the size and actual sequence of the insert at position 69 influence the level of resistance to nucleoside analogues.
authors.affiliation: Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
authors.forename: Lia
authors.initials: L
authors.lastname: van der Hoek
authors.forename: Nicole
authors.initials: N
authors.lastname: Back
authors.forename: Maarten F
authors.initials: MF
authors.lastname: Jebbink
authors.forename: Anthony
authors.initials: A
authors.lastname: de Ronde
authors.forename: Margreet
authors.initials: M
authors.lastname: Bakker
authors.forename: Suzanne
authors.initials: S
authors.lastname: Jurriaans
authors.forename: Peter
authors.initials: P
authors.lastname: Reiss
authors.forename: Neil
authors.initials: N
authors.lastname: Parkin
authors.forename: Ben
authors.initials: B
authors.lastname: Berkhout
mesh_terms: D000328:Adult; D019943:Amino Acid Substitution; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D019143:Evolution, Molecular; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000737:chemistry / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D011995:Recombination, Genetic; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017422:Sequence Analysis, DNA; D014779:Virus Replication; D016047:Zalcitabine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; C050624:2',3'-dideoxycytidinene; D054303:HIV Reverse Transcriptase
references.citation: Antimicrob Agents Chemother. 2000 Apr;44(4):920-8
references.pmid: 10722492
references.citation: Virology. 2000 May 10;270(2):310-6
references.pmid: 10792990
references.citation: J Virol. 2000 Jul;74(14):6262-8
references.pmid: 10864635
references.citation: Antimicrob Agents Chemother. 2000 Aug;44(8):2109-17
references.pmid: 10898683
references.citation: J Virol. 2000 Sep;74(18):8390-401
references.pmid: 10954539
references.citation: J Virol. 2000 Sep;74(18):8524-31
references.pmid: 10954553
references.citation: EMBO J. 2000 Nov 1;19(21):5752-61
references.pmid: 11060026
references.citation: J Virol. 2001 Jan;75(2):589-94
references.pmid: 11134271
references.citation: J Virol. 2001 Jan;75(2):595-602
references.pmid: 11134272
references.citation: Science. 2001 Apr 6;292(5514):7
references.pmid: 11292864
references.citation: Antimicrob Agents Chemother. 2001 Jun;45(6):1836-42
references.pmid: 11353634
references.citation: J Virol. 2001 Jun;75(12):5604-13
references.pmid: 11356968
references.citation: J Virol. 2001 Aug;75(15):7202-5
references.pmid: 11435603
references.citation: Virology. 2001 Jul 5;285(2):193-203
references.pmid: 11437654
references.citation: J Virol. 2001 Oct;75(20):9644-53
references.pmid: 11559796
references.citation: Intervirology. 2001;44(6):339-43
references.pmid: 11805439
references.citation: J Biol Chem. 2002 Feb 22;277(8):5952-61
references.pmid: 11741936
references.citation: AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):733-6
references.pmid: 12167282
references.citation: J Virol. 2002 Sep;76(18):9143-51
references.pmid: 12186898
references.citation: J Virol. 2002 Oct;76(20):10546-52
references.pmid: 12239335
references.citation: J Virol. 2002 Nov;76(21):11104-12
references.pmid: 12368352
references.citation: J Mol Biol. 2002 Oct 18;323(2):181-97
references.pmid: 12381314
references.citation: J Virol. 2003 Mar;77(6):3871-7
references.pmid: 12610164
references.citation: J Virol. 2003 Apr;77(8):5037-8
references.pmid: 12663814
references.citation: AIDS. 2004 Jul 23;18(11):1571-7
references.pmid: 15238775
references.citation: J Clin Microbiol. 1990 Mar;28(3):495-503
references.pmid: 1691208
references.citation: J Infect Dis. 1992 Jan;165(1):105-10
references.pmid: 1370174
references.citation: Virology. 1992 Dec;191(2):968-72
references.pmid: 1448931
references.citation: Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2398-402
references.pmid: 7534421
references.citation: J Infect Dis. 1995 Jun;171(6):1411-9
references.pmid: 7539472
references.citation: J Infect Dis. 1995 Jul;172(1):70-8
references.pmid: 7541064
references.citation: Antimicrob Agents Chemother. 1999 Aug;43(8):1961-7
references.pmid: 10428920
references.citation: J Virol. 1996 Feb;70(2):1086-90
references.pmid: 8551567
references.citation: Science. 1996 Mar 15;271(5255):1582-6
references.pmid: 8599114
references.citation: J Virol. 1996 Apr;70(4):2146-53
references.pmid: 8642636
references.citation: EMBO J. 1996 Aug 1;15(15):4040-9
references.pmid: 8670908
references.citation: J Virol. 1996 Aug;70(8):5662-4
references.pmid: 8764084
references.citation: Antiviral Res. 1996 Jun;31(1-2):45-57
references.pmid: 8793008
references.citation: J Virol. 1997 Apr;71(4):3346-50
references.pmid: 9060708
references.citation: J Virol. 1997 Jun;71(6):4479-84
references.pmid: 9151839
references.citation: J Virol. 1997 Sep;71(9):6662-70
references.pmid: 9261388
references.citation: J Virol. 1998 May;72(5):3773-8
references.pmid: 9557659
references.citation: J Clin Invest. 1998 Nov 15;102(10):1769-75
references.pmid: 9819361
references.citation: AIDS. 1999 Jan 14;13(1):75-80
references.pmid: 10207547
references.citation: J Hum Virol. 1999 May-Jun;2(3):146-53
references.pmid: 10413366